Several significant changes are planned for Medicare Part D in 2025, as part of the Inflation Reduction Act of 2022. These changes are designed to improve affordability for beneficiaries, especially for prescription drug costs. Here are the key updates:
1. $2,000 Out-of-Pocket Cap
Starting in 2025, there will be a $2,000 cap on out-of-pocket costs for prescription drugs under Medicare Part D. This is a major shift, as there has never been a maximum limit on how much beneficiaries can pay for prescription drugs in the program. After hitting this cap, beneficiaries will no longer have to pay coinsurance or copayments for the remainder of the year.
2. Elimination of the 5% Coinsurance in Catastrophic Phase
Currently, once beneficiaries reach the catastrophic phase of Part D (after paying a certain amount in out-of-pocket costs), they are responsible for 5% of the cost of their medications. In 2025, this 5% coinsurance will be eliminated, meaning beneficiaries will no longer have to pay anything in the catastrophic coverage phase.
3. Monthly “Smoothing” of Out-of-Pocket Costs
Beneficiaries will be allowed to “smooth” or spread out their out-of-pocket costs over the year, instead of paying large sums upfront when filling prescriptions. This will help reduce the financial burden on people who have high drug costs early in the year.
4. Expanded Low-Income Subsidy (LIS) Eligibility
Eligibility for the Extra Help/Low-Income Subsidy (LIS) program, which helps pay for Part D premiums and drug costs, will be expanded to people with incomes up to 150% of the federal poverty level. Currently, full subsidies are only available to those with incomes up to 135% of the federal poverty level. This change will make more people eligible for assistance with their drug costs.
5. Inflation Rebates for Drug Price Increases
Pharmaceutical companies will be required to pay rebates if they raise the prices of their drugs faster than inflation. This provision aims to help control the rising cost of prescription drugs.
These reforms are expected to offer substantial financial relief to seniors and individuals with disabilities who rely on Medicare Part D, particularly those with high prescription drug costs.